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Abstract
Background: We investigated the contribution of subsequent therapy for advanced hepatocellular carcinoma
refractory or intolerant to sorafenib. Further, we investigated the impact of sorafenib on overall survival using
individual data.
Methods: We reviewed the medical records of patients with advanced hepatocellular carcinoma treated with
sorafenib. Survival after sorafenib treatment and overall survival were defined as the time when we discovered
that patients were either refractory or intolerant to sorafenib and the period from the start of sorafenib treatment,
respectively, until death during the study. We compared patients’ prognoses according to their subsequent
treatment as follows: group A, therapies targeting intrahepatic lesions; group B, systemic therapies alone;
group C, no subsequent therapy. We used linear regression analysis to determine whether there was an
association with survival after sorafenib treatment and with overall survival.
Results: Of 79 patients, 63 (79.7 %) received one or more subsequent therapies (44 and 19 patients in groups A
and B, respectively). The five patients who survived more than two years after sorafenib treatment was discontinued
responded to therapies targeting intrahepatic lesions. The median survival times of groups A, B, and C were 11.9
months, 5.8 months, and 3.6 months, respectively. Multivariate analysis revealed that group A, Child-Pugh
score, serum α-fetoprotein level, and cause of failure of sorafenib treatment were independent prognostic
factors for survival after sorafenib treatment. Individual survival after sorafenib treatment correlated highly
with overall survival.
Conclusions: Targeting intrahepatic lesions may be useful for treating patients with advanced hepatocellular
carcinoma patients after sorafenib treatment is discontinued.
Keywords: Hepatocellular carcinoma, Sorafenib, Subsequent therapy, Posttreatment survival, Hepatic arterial
infusion chemotherapy
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Background
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related mortality worldwide [1]. A var-
iety of new imaging techniques detect HCC at early
stages [2]. However, the number of patients with HCC
who can be treated curatively is limited owing to impaired
hepatic reserve and frequent metachronous recurrence to
become difficult to treat. Therefore, the prognosis of
patients with advanced HCC remains poor [3]. Sorafenib,
an orally administered multikinase inhibitor that blocks
tumor cell proliferation and angiogenesis, represents the
only systemic drug that significantly improves overall sur-
vival (OS) of patients with advanced HCC [4]. Therefore,
sorafenib is recognized as standard first-line therapy for
advanced HCC [5, 6].
Previous analyses suggest that the survival of patients
with HCC who are refractory or intolerant to sorafenib
correlates highly with OS, whereas progression-free
survival correlates less well with OS of patients with
advanced HCC [7, 8]. These results are unexpected,
because randomized trials fail to show that drugs that
were administered after discontinuation of sorafenib
treatment are effective for treating HCC [9]. Therefore,
longer treatment with sorafenib may correlate directly
with improvement of OS of patients with advanced HCC
[10]. One of the possible reasons for the strong correl-
ation between survival after sorafenib treatment and OS
may be the beneficial role of subsequent therapy such as
hepatic arterial infusion chemotherapy [11], transarterial
chemoembolization [12], or continuation of sorafenib
beyond progression [13] that increases survival after pro-
longed treatment with sorafenib. However, the effects of
these treatments in clinical practice remain unclear.
The aim of the present study is to investigate treat-
ment strategies and the contribution of subsequent ther-
apies, particularly those targeting intrahepatic lesions, by
identifying prognostic factors for patients with advanced
HCC after sorafenib treatment in study 1. Moreover, we
investigated the effect of posttreatment survival after
sorafenib treatment on OS in study 2. We show here
that this approach provides useful information for
designing an optimal treatment strategy for advanced
HCC after treatment with sorafenib.
Methods
Patients
The subjects were consecutive patients with advanced
HCC treated with sorafenib monotherapy at the Kanazawa
University Hospital between June 2009 and October 2014.
All patients underwent dynamic computed tomography
(CT) to diagnose and assess the extent of the cancer.
HCC was diagnosed according to the guidelines of the
American Association for the Study of Liver Disease
guidelines [14]. Patients received 400 mg of sorafenib
orally twice daily. Treatment was temporarily interrupted
or reduced according to toxicity and was continued until
the confirmation of tumor progression or the occurrence
of unacceptable adverse effects. Patients were considered
as candidates for subsequent therapy in study 1 if, at the
time of their refractory response or intolerance to sorafe-
nib, their characteristics were as follows: Eastern Coopera-
tive Oncology Group performance status = 0 or 1;
appropriate function of major organs, including bone mar-
row, kidney, and cardiac function; and hepatic reserve
with Child-Pugh class A or B. Of the patients included in
study1, those who were alive at the last visit before the
time of analysis were excluded, and only patients with
confirmed survival data were included in study 2.
Evaluation
To assess the antitumor effects of sorafenib, dynamic
CT was conducted every six weeks during treatment and
at the time of a refractory response or intolerance to
sorafenib. Responses were assessed according to the
Response Evaluation Criteria in Solid Tumors ver. 1.1
[15]. We reviewed patients’ medical records and collected
demographic, clinical, and laboratory data including age,
sex, Eastern Cooperative Oncology Group performance
status, history of viral infection, factors related to hepatic
reserve associated with Child-Pugh classification, imaging
data (vascular invasion and extrahepatic spread of HCC),
and tumor markers at the time of a refractory response or
intolerance to sorafenib. We further investigated the cause
of failure of sorafenib treatment (refractory response or
intolerance).
“Survival after sorafenib”, time to treatment failure of
sorafenib treatment, and OS was defined as follow in
this study. Survival after sorafenib treatment was de-
fined as the time of a refractory response or intoler-
ance to sorafenib until death [16]. “Time to treatment
failure of sorafenib treatment” was defined as the
time from the start of sorafenib treatment until the
time of a refractory response or intolerance to sorafe-
nib. “OS” was defined as the period from start of so-
rafenib treatment until death and that is sum of time
to treatment failure of sorafenib treatment and survival
after sorafenib treatment.
Statistical analysis
We first divided the patients into three groups ac-
cording to their treatment after sorafenib treatment
as follows. Those who received one or more therapies
targeting intrahepatic lesions, including hepatic arter-
ial infusion chemotherapy, transarterial chemoemboli-
zation, radio frequency ablation, and radiotherapy for
intrahepatic lesion were classified as group A. Those
who received only systemic therapy, including sys-
temic cytotoxic chemotherapy, molecular targeted
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therapy, immunotherapy, and radiotherapy for extra-
hepatic lesions were classified as group B. Those who
did not receive any subsequent therapy were classified
as group C.
Categorical variables were compared using the chi-
squared test when appropriate. For univariate analysis,
the cumulative survival frequencies were calculated
using Kaplan–Meier analysis that considered different
clinical factors likely associated with survival after soraf-
enib treatment, and the differences were evaluated using
the log-rank test. Only variables with p < 0.1 in univari-
ate analysis were subsequently evaluated in multivariate
analysis using the Cox’s proportional hazards regression
model, and p < 0.05 was considered statistically signifi-
cant. The relationship between OS and either survival
after sorafenib treatment or time to treatment failure of
sorafenib treatment were estimated using weighted lin-
ear regression analysis. All statistical analyses were per-
formed using the SPSS statistical software program
package (SPSS Inc., Chicago, IL, USA).
This was non-invasive retrospective observation study,
and then, the need for individual consent is deemed
unnecessary according to Japanese nation regulation,
Ethical Guidelines for Medical and Health Research
Involving Human Subjects (available: http://www.mhlw.
go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukous
eikagakuka/0000080278.pdf). The protocol of this study
was approved by the institutional review board at
Kanazawa University and the study was conducted in
accordance with the Declaration of Helsinki.
Results
Patient characteristics
The data collection ended March 7, 2015. We reviewed
retrospectively 99 consecutive patients with advanced
HCC who were treated with sorafenib monotherapy in
our institution between June 2009 and October 2014.
We were unable to acquire sufficient information about
survival after sorafenib treatment for seven patients,
and 13 patients did not meet the selection criteria for
subsequent therapy. Thus, 79 subjects were included
in study 1 (Fig. 1).
The median time to treatment failure of sorafenib
treatment of these 79 patients was 2.56 months (range,
0.03–17.75 months) (Additional file 1: Figure S1). The
response rate and tumor control rate for sorafenib treat-
ment were 2.5 % and 53.2 %, respectively, in accordance
with Response Evaluation Criteria in Solid Tumors
ver1.1. Sorafenib was terminated because of tumor pro-
gression (refractory to sorafenib) for 59 patients (74.7 %)
and unacceptable adverse effects (intolerant to sorafenib)
for 20 patients (25.3 %).
Treatment strategy after discontinuation of sorafenib
treatment
The median follow-up period for survival after sorafenib
treatment and OS were 6.6 months and 9.8 months,
respectively. Sixty-three patients (79.7 %) received one or
more subsequent therapies after sorafenib treatment, in-
cluding hepatic arterial infusion chemotherapy (n = 37),
systemic cytotoxic chemotherapy (n = 22), transarterial
Fig. 1 Study population. The target population of this study comprised patients with advanced HCC pretreated with sorafenib and those who
were considered as candidates for subsequent therapy and were included in study 1. Patients who died before the analysis were included in
study 2
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chemoembolization (n = 12), molecular targeted therapy
or continuous administration of sorafenib (n = 11), im-
munotherapy (n = 10), radiofrequency ablation (n = 7),
and radiotherapy of intrahepatic lesions (n = 4). The
remaining 16 patients (20.3 %) received appropriate infor-
mation about available treatment options, which they
declined. There were 44, 19, and 16 patients were
classified as group A (those who received one or
more therapies targeting intrahepatic lesions), B
(those who received only systemic therapy), and C
(those who did not receive any subsequent therapy),
respectively.
Patients’ demographics at the time of a refractory re-
sponse or intolerance to sorafenib are summarized in
Table 1. There was no statistically significant difference
among groups.
Survival after sorafenib according to subsequent therapy
Median survival times after a refractory response or in-
tolerance to sorafenib for patients in groups A, B, and C
were 11.9, 5.8, and 3.6 months, respectively. Survival
after sorafenib treatment of group A was significantly
longer compared with that of group C (p < 0.001)
(Fig. 2).
Taking into consideration the median follow-up
period as described above, we consider the patients
who survived longer than two years after discontinu-
ation of sorafenib treatment as long survivor, and
their characteristics are shown in Table 2. They all
responded to subsequent therapies targeting intrahe-
patic lesions, and three of the four patients who
received hepatic arterial infusion chemotherapy
achieved a partial response.
Table 1 Patient characteristics at the time of a refractory response or intolerance to sorafenib treatment
Total group A group B group C P value*
(n = 79) (n = 44) (n = 19) (n = 16)
Age, years 0.67
≥68 43 (54.4) 23 (52.3) 12 (63.2) 8 (50.0)
Gender 0.72
Male 71 (89.9) 39 (88.6) 18 (94.7) 14 (87.5)
ECOG performance status 0.46
0 50 (63.3) 29 (65.9) 13 (68.4) 8 (50.0)
1 29 (36.7) 15 (34.1) 6 (31.6) 8 (50.0)
hepatitis B surface antigen 0.33
Positive 27 (34.2) 16 (36.4) 4 (21.1) 7 (43.8)
hepatitis C virus antibody 0.82
Positive 34 (43.0) 20 (45.5) 7 (36.8) 7 (43.8)
Child-Pugh class (Child-Pugh score) 0.064
A (5) 21 (26.6) 11 (25.0) 7 (36.8) 3 (18.8)
A (6) 27 (34.2) 19 (43.2) 6 (31.6) 2 (12.5)
B 31 (39.2) 14 (31.8) 6 (31.6) 11 (68.8)
Vascular invasion 0.097
Positive 26 (32.9) 15 (34.1) 3 (15.8) 8 (50.0)
Extra-hepatic spread 0.62
Positive 43 (54.4) 22 (50.0) 12 (63.2) 9 (56.3)
AFP a, n (%) 0.87
≥400 ng/mL 29 (36.7) 17 (38.6) 6 (31.6) 6 (37.5)
Cause of failure of sorafenib treamtnet 0.080
Tumor progression 60 (75.9) 37 (84.1) 14 (73.7) 9 (56.3)
Adverse effect 19 (24.1) 7 (15.9) 5 (26.3) 7 (43.8)
Time to treatment failure of sorafenib, months 0.059
<2.56 39 (49.4) 20 (45.5) 7 (36.8) 12 (75.0)
≥2.56 40 (50.6) 24 (54.5) 12 (63.2) 4 (25.0)
a AFP α-fetoprotein
*chi-squared test
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Prognostic factors of survival after sorafenib treatment
Univariate analyses identified four of the 11 variables
that were significantly associated with prognostic factors
of survival after sorafenib treatment (Table 3) as follows:
Child-Pugh class, serum AFP level, cause of failure of so-
rafenib treatment as well as subsequent therapies target-
ing intrahepatic lesions. Independent factors that were
unfavorable for survival after sorafenib treatment were
as follows: no subsequent therapy, subsequent systemic
therapies alone, Child-Pugh class B, Child-Pugh score 6,
400 ng/mL or higher serum AFP level, and discontinu-
ation of sorafenib due to tumor progression (Table 3).
Correlation between OS and survival after sorafenib
treatment or time to treatment failure
Sixteen patients were alive at the last visit before the
time of the analysis, and the correlation between OS and
survival after sorafenib treatment or time to treatment
Fig. 2 Kaplan–Meier analysis of survival. The median survival after sorafenib treatment of patients in group A (patients receiving therapies
targeting intrahepatic lesions; black line), group B (patients receiving systemic therapy alone, gray line), and group C (no subsequent therapy,
dashedline) were 11.9, 5.8 and 3.6 months, respectively. Survival after sorafenib treatment of group A was significantly longer compared with
that of group C (p < 0.001)
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failure of sorafenib treatment was assessed among the
remaining 63 patients with confirmed data (Fig. 1).
Median OS and survival after sorafenib treatment
were 10.1 months and 6.7 months. The OS data were
plotted against survival after sorafenib treatment
(Fig. 3a) and time to treatment failure of sorafenib
treatment (Fig. 3b). We found that survival after so-
rafenib treatment highly correlated with OS (r =
0.949), while time to treatment failure of sorafenib
treatment did not well correlate with OS (r = 0.508).
These differences were more apparent in the sub-
group of Child-Pugh class A compared with B, BCLC
stage B compared with C, discontinuation of sorafenib
because of adverse effects compared with tumor pro-
gression, and any subsequent therapy compared with
no subsequent therapy (Table 4).
Table 3 Prognostic factors affecting survival after sorafenib treatment
n Median survival after sorafenib,
months




≥68 43 9.7 0.65
<68 36 9.3
Gender
Male 71 9.3 0.78
Female 8 9.5
hepatitis B surface antigen
Positive 27 10.5 0.67
Negative 52 9.4
hepatitis C virus antibody
Negative 45 9.2 0.90
Positive 34 9.5
Child-Pugh class (Child-Pugh score)
B 31 4.7 0.070 2.999 (1.478-6.087) 0.009
A (6) 27 11.9 2.328 (1.109-4.884) 0.025
A (5) 21 9.9
Vascular invasion
Positive 26 6.7 0.29
Negative 53 9.9
Extra-hepatic lesion
Positive 43 6.6 0.12
Negative 36 9.7
AFP a, ng/mL
≥400 29 4.3 0.032 2.207 (1.230-3.958) 0.008
<400 50 9.9
Cause of failure of sorafenib treatment
Tumor progression 60 8.1 0.045 2.331 (1.168-4.650) 0.016
Adverse effect 19 13.5
Time to treatment failure of sorafenib treatment, months
<2.56 39 8.1 0.49
≥2.56 40 9.9
Subsequent therapy
group C 16 3.6 0.001 5.805 (2.684-12.553) <0.001
group B 19 5.8 2.628 (1.309-5.278) 0.007
group A 44 11.9
a AFP: α-fetoprotein
*Log-rank test, **Cox’s proportional hazards regression model
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Discussion
We show here that therapies targeting intrahepatic le-
sions administered after discontinuing sorafenib treat-
ment represented one of the independent prognostic
factors for patients with advanced HCC. This finding
has important implications for designing treatment strat-
egies for such patients. Factors such as general health,
hepatic reserve, and tumor-associated factors such as
vascular invasion and serum AFP levels predict the out-
comes of patients with advanced HCC [17], and the pro-
gression pattern and cause of failure of sorafenib
treatment stratifies patients’ outcomes [18]. Our present
results show that subsequent therapy targeting intrahe-
patic lesions was a prognostic factor independent of
Child-Pugh score, serum AFP level, and the reason for
discontinuing sorafenib treatment. A report refers to the
possible role of subsequent therapy [17]; however, they
do not consider patients’ conditions or other confound-
ing factors. We excluded patients whose performance
status was poor, and their liver function was decompen-
sated. Therefore, the objectives were restricted to pa-
tients considered as candidates for any subsequent
therapy in this study.
Our findings suggest that treatment procedures target-
ing intrahepatic lesions were useful for increasing
survival after sorafenib treatment. Although extrahepatic
lesions are often observed in patients with advanced
HCC, they are only 7.6 % of cause of death [19]. More-
over, the presence of intrahepatic lesions is one of the
prognostic factors for radiologic progression and OS for
patients with HCC, even those with extrahepatic spread
treated with sorafenib [13]. Therefore, good control of
intrahepatic lesions may affect the prognosis of these
patients [20].
Although local therapies targeting intrahepatic lesions
such as hepatic arterial infusion chemotherapy, transar-
terial chemoembolization, radiofrequency ablation, or
radiotherapy are conventionally administered to reduce
the tumor burden of patients after sorafenib treatment,
no prospective trials, to our knowledge, verify their
benefit for survival. Our present results indicate that
such therapies may serve as promising treatment strat-
egies, even after patients are administered systemic
sorafenib.
The results of the present nonrandomized study
should be interpreted with caution because of potential
confounding factors affecting treatment strategy. Some
different factors were observed between groups includ-
ing the hepatic reservation, cause of sorafenib discon-
tinuation, and time to treatment failure of sorafenib
Fig. 3 Linear regression analysis of overall survival and survival after sorafenib treatment and time to treatment failure of sorafenib treatment.
a Survival after sorafenib treatment correlated significantly with overall survival (r = 0.949). b Time to treatment failure of sorafenib treatment
correlated with overall survival (r = 0.508) as well
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treatment, although the differences were not statisti-
cally significant (Table 1). Further, the outcomes were
possibly affected by unidentified factors that were
unique to group C. However, although the retrospect-
ive design did not allow us to reach a definitive con-
clusion, the results of multivariate analysis support a
beneficial effect of therapies that target intrahepatic
lesions, and the significance of the effects of these
treatments should be noticeable under certain circum-
stances. For example, the control group should be
treated with best available therapy that target intrahe-
patic lesions in clinical trials designed to evaluate
new agents. The proportion of patients receiving ther-
apies that target intrahepatic lesions subsequent to
sorafenib treatment should be considered in the ana-
lysis of the outcomes of clinical trials. More aggres-
sive application of subsequent therapy that target
intrahepatic lesions should be considered to target
intrahepatic lesions in clinical practice.
The participants of a workshop held at the 50th
Annual Meeting of the Liver Cancer Study Group of
Japan issued a list of five factors related to long-term
survival of patients with HCC that includes effective
post-sorafenib options [21]. The long-term effect of
sorafenib is restricted owing to its static antitumor
activity and numerous types of toxicities [4, 22],
which are consistent with our finding that the sorafe-
nib treatment was successful for 1 year for only two
patients (2.5 %) (Additional file 1: Figure S1). In con-
trast, others reported responses of approximately 30
% of patients treated with hepatic arterial infusion
chemotherapy, and long-term survival was expected
in such patients [11]. It is important to note that
hepatic arterial infusion chemotherapy is effective
when administered after sorafenib and its efficacy is
independent of sorafenib treatment.
Finally, we believe that our present finding that
survival after sorafenib treatment correlated highly
with OS, which was determined according to individ-
ual data, is very important. Further, survival after
sorafenib treatment was not significantly stratified ac-
cording to the efficacy of sorafenib treatment. These
findings suggest that patients with HCC who did not
obtain a satisfactory benefit from sorafenib treatment
may benefit from subsequent therapies. The signifi-
cance of survival after sorafenib treatment should be
noted for the conditions as follows: The duration of
survival after sorafenib treatment should be carefully
estimated when calculating the sample size of clinical
trials, and survival after sorafenib treatment should
be considered in the analysis of the outcomes of
clinical trials.
Table 4 Analysis of overall survival and survival after sorafenib treatment or time to treatment failure of sorafenib treatment
n OS a and survival after sorafenib treatment OS a and time to treatment failure of sorafenib treatment
R P value* r P value*
All patients
63 0.949 <0.001 0.508 <0.001
Child-Pugh class (Child-Pugh score)
A (5) 14 0.992 <0.001 0.176 0.56
A (6) 21 0.944 <0.001 0.687 <0.001
B 28 0.920 <0.001 0.570 0.001
BCLC stage
B 16 0.968 <0.001 0.313 0.24
C 47 0.940 <0.001 0.555 <0.001
AFP b, ng/mL
≥400 25 0.947 <0.001 0.490 0.012
<400 38 0.948 <0.001 0.500 0.001
Cause of failure of sorafenib treatment
Tumor progression 49 0.939 <0.001 0.596 <0.001
Adverse effect 14 0.989 <0.001 0.363 0.21
Subsequent therapy
No 13 0.880 <0.001 0.428 0.15
Any 50 0.947 <0.001 0.471 <0.001
a OS overall survival
b AFP α-fetoprotein
*linear regression analysis
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Our study has several limitations such as its retro-
spective design and the acquisition of data from a single
institution. A properly designed prospective trial with a
large number of subjects is required to confirm the sig-
nificance of the effects of subsequent therapies targeting
intrahepatic lesions.
Conclusion
In conclusion, survival after sorafenib treatment was
dependent on subsequent therapies targeting intrahepa-
tic lesions, Child-Pugh score, serum AFP level, and the
reason for discontinuing sorafenib treatment. Conven-
tional post-sorafenib therapies, particularly those target-
ing intrahepatic lesions, such as hepatic arterial infusion
chemotherapy, palliative transarterial chemoemboliza-
tion, radiofrequency ablation, or radiotherapy may be
useful. Therefore, we recommended them for patients
with advanced HCC after sorafenib treatment is
discontinued.
Additional file
Additional file 1: Figure S1. Kaplan–Meier analysis of time to
treatment failure of sorafenib.treatment. Median time to treatment
failure for all patients was 2.56 months. (TIF 32 kb)
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